Production (Stage)
Revelation Biosciences, Inc.
REVB
$2.97
$0.103.48%
NASDAQ
| 03/31/2025 | 12/31/2024 | 09/30/2024 | 06/30/2024 | 03/31/2024 | |
|---|---|---|---|---|---|
| Revenue | -- | -- | -- | -- | -- |
| Total Other Revenue | -- | -- | -- | -- | -- |
| Total Revenue | -- | -- | -- | -- | -- |
| Cost of Revenue | -- | -- | -- | -- | -- |
| Gross Profit | -- | -- | -- | -- | -- |
| SG&A Expenses | 4.36% | -9.28% | -14.27% | 10.13% | 8.22% |
| Depreciation & Amortization | -- | -- | -- | -- | -- |
| Other Operating Expenses | -- | -- | -- | -- | -- |
| Total Operating Expenses | 10.14% | -24.59% | -35.32% | 30.49% | 17.43% |
| Operating Income | -10.14% | 24.59% | 35.32% | -30.49% | -17.43% |
| Income Before Tax | 23.51% | 21.66% | 14.72% | -479.33% | -143.53% |
| Income Tax Expenses | -- | -- | -- | -- | -- |
| Earnings from Continuing Operations | 23.51% | 21.66% | 14.72% | -479.33% | -143.53% |
| Earnings from Discontinued Operations | -- | -- | -- | -- | -- |
| Extraordinary Item & Accounting Change | -- | -- | -- | -- | -- |
| Minority Interest in Earnings | -- | -- | -- | -- | -- |
| Net Income | 23.51% | 21.66% | 14.72% | -479.33% | -143.53% |
| EBIT | -10.14% | 24.59% | 35.32% | -30.49% | -17.43% |
| EBITDA | -10.12% | 24.70% | 35.43% | -30.54% | -17.50% |
| EPS Basic | 94.64% | -- | -- | -- | -- |
| Normalized Basic EPS | 94.64% | -- | -- | -- | -- |
| EPS Diluted | 94.64% | -- | -- | -- | -- |
| Normalized Diluted EPS | 94.64% | -- | -- | -- | -- |
| Average Basic Shares Outstanding | 1,326.28% | -- | -- | -- | -- |
| Average Diluted Shares Outstanding | 1,326.28% | -- | -- | -- | -- |
| Dividend Per Share | -- | -- | -- | -- | -- |
| Payout Ratio | -- | -- | -- | -- | -- |